New-drug sales boost plus OTC buyout yields $53B forecast for Bayer

Carly Helfand

is already coasting along -wise, with some powerhouse new drugs helping it beat analysts' third-quarter forecasts. And those will only keep on growing, the company said Thursday as it raised its revenue and profit forecasts.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS